
 
 
 
 
 
 
 
 
 The invention claimed is: 
   
 1. A compound of formula I: 
 
 
 
 
   
   
 
 
 or a pharmaceutically acceptable salt thereof, wherein: 
 the square brackets indicate the NO 2  group is optional; 
 D represents either group D1 or D2: 
 
 
 
 
 
   
   
 
 
 the dotted line indicates the optional presence of a double bond between C2 and C3; 
 when there is a double bond present between C2 and C3, R 2  is selected from the group consisting of:
 (ia) phenyl, naphthyl, azulenyl or C 5-10  heteroaryl, optionally substituted by one or more substituents selected from the group consisting of: halo, nitro, cyano, —OR B , carboxy, C(═O)OR B , C 1-7  alkyl, C 3-7  heterocyclyl and bis-oxy-C 1-3  alkylene, wherein R B  is selected from a C 1-7  alkyl group, a C 3-20  heterocyclyl group or a phenyl, naphthyl, azulenyl, anthracenyl, phenanthrenyl, napthacenyl, pyrenyl, or C 5-20  heteroaryl; 
 (ib) C 1-5  saturated aliphatic alkyl; 
 (ic) C 3-6  saturated cycloalkyl; 
 
 
 
 
 
 
   
   
 
 
 
 wherein each of R 11 , R 12  and R 13  are independently selected from H, C 1-3  saturated alkyl, C 2-3  alkenyl, C 2-3  alkynyl and cyclopropyl, where the total number of carbon atoms in the R 2  group is no more than 5; 
 
 
 
 
   
   
 
 
 
 wherein one of R 15a  and R 15b  is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and 
 
 
 
 
   
   
 
 
 
 where R 14  is selected from: H; C 1-3  saturated alkyl; C 2-3  alkenyl; C 2-3  alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
 when there is a single bond present between C2 and C3, 
 R 2  is selected from H, OH, F, diF and 
 
 
 
 
 
   
   
 
 
 
 where R 16a  and R 16b  are independently selected from H, F, C 1-4  saturated alkyl, C 2-3  alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C 1-4  alkyl amido and C 1-4  alkyl ester; or, when one of R 16a  and R 16b  is H, the other is selected from nitrile and a C 1-4  alkyl ester;
 D′ represents either group D′1 or D′2: 
 
 
 
 
 
   
   
 
 
 wherein the dotted line indicates the optional presence of a double bond between C2′ and C3′; 
 when there is a double bond present between C2′ and C3′, R 12  is selected from the group consisting of: 
 (iia) phenyl, naphthyl, azulenyl or C 5-10  heteroaryl, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, —OR B , carboxy, —C(═O)OR B , C 1-7  alkyl, C 3-7  heterocyclyl and bis-oxy-C 1-3  alkylene, wherein R B  is selected from a C 1-7  alkyl group, a C 3-20  heterocyclyl group or a phenyl, naphthyl, azulenyl, anthracenyl, phenanthrenyl, napthacenyl, pyrenyl or C 5-20  heteroaryl; 
 (iib) C 1-5  saturated aliphatic alkyl; 
 (iic) C 3-6  saturated cycloalkyl; 
 
 
 
 
 
   
   
 
 
 
 wherein each of R 21 , R 22  and R 23  are independently selected from H, C 1-3  saturated alkyl, C 2-3  alkenyl, C 2-3  alkynyl and cyclopropyl, where the total number of carbon atoms in the R 12  group is no more than 5; 
 
 
 
 
   
   
 
 
 
 wherein one of R 25a  and R 25b  is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and 
 
 
 
 
   
   
 
 
 
 where R 24  is selected from: H; C 1-3  saturated alkyl; C 2-3  alkenyl; C 2-3  alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
 when there is a single bond present between C2′ and C3′, 
 R 12  is selected from H, OH, F, diF and 
 
 
 
 
 
   
   
 
 
 
 where R 26a  and R 26b  are independently selected from H, F, C 1-4  saturated alkyl, C 2-3  alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C 1-4  alkyl amido and C 1-4  alkyl ester; or, when one of R 26a  and R 26b  is H, the other is selected from nitrile and a C 1-4  alkyl ester;
 R 6  and R 9  are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; 
 where R and R′ are independently selected from C 1-12  alkyl, C 3-20  heterocyclyl and phenyl, naphthyl, azulenyl, anthracenyl, phenanthrenyl, napthacenyl, pyrenyl or C 5-20  heteroaryl; 
 R 7  is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; 
 R″ is a C 3-12  alkylene group, which chain may be interrupted by one or more heteroatoms selected from O, S, NR N2  (where R N2  is H or C 1-4  alkyl), and/or aromatic rings selected from benzene or pyridine; 
 Y and Y′ are selected from O, S, or NH; 
 R 6′ , R 7′ , R 9′  are selected from the same groups as R 6 , R 7  and R 9  respectively; 
 R 11b  is selected from OH, OR A , where R A  is C 1-4  alkyl; and 
 R L  is a linker for connection to a cell binding agent, which is: 
 
 
 
 
 
   
   
 
 
 wherein 
 Q is: 
 
 
 
 
 
   
   
 
 
 
 where Q X  is such that Q is an amino-acid residue, a dipeptide residue or a tripeptide residue;
 X is: 
 
 
 
 
 
   
   
 
 
 where a=0 to 5, b=0 to 16, c=0 or 1, =0 to 5; 
 G L  is selected from: 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 where Ar is phenylene; 
 wherein the heterocyclyl group in C 3-7  heterocyclyl contains 1 to 4 ring heteroatoms selected from N, O and S; 
 wherein the heterocyclyl group in C 3-20  heterocyclyl contains 1 to 10 ring heteroatoms selected from N, O and S; and 
 wherein the heteroaryl group in C 5-10  heteroaryl contains 1 to 4 ring heteroatoms selected from N, O and S 
 wherein the heteroaryl group in C 5-20  heteroaryl contains 1 to 10 ring heteroatoms selected from N, O and S. 
 
 
     
 2. A compound according to  claim 1 , wherein:
 a) both Y and Y′ are O; and/or 
 b) R″ is C 3-7  alkylene or a group of formula: 
 
 
 
 
 
   
   
 
 
 where r is 1 or 2; and/or 
 c) R 9  is H; and/or 
 d) R 6  is H; and/or 
 e) R 7  is selected from H, OH and OR or a C 1-4  alkyloxy group. 
 
 
     
 3. A compound according to  claim 1 , wherein:
 a) D is D1, there is a double bond between C2 and C3, and R 2  is a C 5-7  aryl group, wherein R 2  optionally bears one to three substituent groups selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl; or 
 b) D is D1, there is a double bond between C2 and C3, and R 2  is a C 8-10  aryl group, wherein R 2  optionally bears one to three substituent groups selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl; or 
 c) D is D1, there is a double bond between C2 and C3, and R 2  is methyl, ethyl or propyl; or 
 d) there is a double bond between C2 and C3, and R 2  is cyclopropyl; or 
 e) wherein D is D1, there is a double bond between C2 and C3, and R 2  is a group of formula: 
 
 
 
 
 
   
   
 
 
 wherein:
 i) the total number of carbon atoms in the R 2  group is no more than 4; and/or 
 ii) one of R 11 , R 12  and R 13  is H, with the other two groups being selected from H, C 1-3  saturated alkyl, C 2-3  alkenyl, C 2-3  alkynyl and cyclopropyl; or 
 iii) two of R 11 , R 12  and R 13  are H, with the other group being selected from H, C 1-3  saturated alkyl, C 2-3  alkenyl, C 2-3  alkynyl and cyclopropyl; or 
 
 f) D is D1, there is a double bond between C2 and C3, and R 2  is the group: 
 
 
 
 
 
   
   
 
 
 
 or
 g) D is D1, there is a double bond between C2 and C3, and R 2  is a group of formula: 
 
 
 
 
 
   
   
 
 
 wherein R 14  is selected from H, methyl, ethyl, ethenyl and ethynyl. 
 
 
     
 4. A compound according to  claim 1 , wherein
 a) D is D1, there is a single bond between C2 and C3, and R 2  is H; or 
 b) D is D1, there is a single bond between C2 and C3, R 2  is 
 
 
 
 
 
   
   
 
 
 
 and R 16a  and R 16b  are both H; or
 c) D is D1, there is a single bond between C2 and C3, R 2  is 
 
 
 
 
 
   
   
 
 
 
 and R 16a  and D 16b  are both methyl; or
 d) D is D1, there is a single bond between C2 and C3, R 2  is 
 
 
 
 
 
   
   
 
 
 
 one of R 16a  and R 16b  is H, and the other is selected from C 1-4  saturated alkyl. 
 
     
 5. A compound according to  claim 1 , wherein:
 a) D′ is D′1, there is a double bond between C2′ and C3′, and R 12  is a C 5-7  aryl group, wherein R 12  optionally bears one to three substituent groups selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl; or 
 b) D′ is D′1, there is a double bond between C2′ and C3′, and R 12  is a C 8-10  aryl group, wherein R 12  optionally bears one to three substituent groups selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl; or 
 c) D′ is D′1, there is a double bond between C2′ and C3′, and R 12  is methyl, ethyl or propyl; or 
 d) D′ is D′1, there is a double bond between C2′ and C3′, and R 12  is cyclopropyl; or 
 e) D′ is D′1, there is a double bond between C2′ and C3′, and R 12  is a group of formula: 
 
 
 
 
 
   
   
 
 
 wherein:
 i) the total number of carbon atoms in the R 12  group is no more than 3; 
 ii) one of R 21 , R 22  and R 23  is H, with the other two groups being selected from H, C 1-3  saturated alkyl, C 2-3  alkenyl, C 2-3  alkynyl and cyclopropyl; or 
 iii) two of R 21 , R 22  and R 23  are H, with the other group being selected from H, C 1-3  saturated alkyl, C 2-3  alkenyl, C 2-3  alkynyl and cyclopropyl; or 
 
 f) D′ is D′1, there is a double bond between C2′ and C3′, and R 12  is the group: 
 
 
 
 
 
   
   
 
 
 
 or
 g) D′ is D′1, there is a double bond between C2′ and C3′, and R 12  is a group of formula: 
 
 
 
 
 
   
   
 
 
 
 wherein R 24  is selected from H, methyl, ethyl, ethenyl and ethynyl. 
 
     
 6. A compound according to  claim 1 , wherein
 a) D′ is D′1, there is a single bond between C2′ and C3′, and R 12  is H; or 
 b) D′ is D′1, there is a single bond between C2′ and C3′, R 12  is 
 
 
 
 
 
   
   
 
 
 
 and R 26a  and R 26b  are both H; or
 c) D′ is D′1, there is a single bond between C2′ and C3′, R 12  is 
 
 
 
 
 
   
   
 
 
 
 and R 26a  and R 26b  are both methyl; or
 d) D′ is D′1, there is a single bond between C2′ and C3′, R 12  is 
 
 
 
 
 
   
   
 
 
 
 one of R 26a  and R 26b  is H, and the other is selected from C 1-4  saturated alkyl, C 2-3  alkenyl. 
 
     
 7. A compound according to  claim 1 , wherein:
 a) R 6′  is selected from the same groups as R 6 , R 7′  is selected from the same groups as R 7 , R 9′  is selected from the same groups as R 9  and Y′ is selected from the same groups as Y; and/or 
 b) R 6′  is the same groups as R 6 , R 7′  is the same groups as R 7 , R 9′  is the same groups as R 9  and Y′ is the same groups as Y; and/or 
 c) R 12  is the same group as R 2 . 
 
 
     
 8. A compound according to  claim 1 , which is of formula Ia-1, Ia-2 or Ia-3: 
 
 
 
 
   
   
 
 
 where R 2a  and R 12a  are the same and are selected from: 
 
 
 
 
 
   
   
 
 
 R 1a  is selected from methyl and benzyl; 
 R L  and R 11b  are as defined in  claim 1 . 
 
 
     
 9. A compound according to  claim 1 , wherein both R 2  and R 12  comprise no more than 3 carbon atoms. 
 
     
 10. A compound according to  claim 1 , wherein R llb  is OH or OR A , where R A  is C 1-4  alkyl, optionally wherein R A  is methyl. 
 
     
 11. A compound according to  claim 1 , wherein Q X  is:
 a) an amino acid residue selected from Phe, Lys, Val, Ala, Cit, Leu, Ile, Arg, and Trp; or 
 b) a dipeptide residue selected from:
   CO -Phe-Lys- NH , 
   CO -Val-Ala- NH , 
   CO -Val-Lys- NH , 
   CO -Ala-Lys- NH , 
   CO _Val-Cit- NH , 
   CO -Phe-Cit- NH , 
   CO -Leu-Cit- NH , 
   CO -Ile-Cit- NH , 
   CO -Phe-Arg- NH , and 
   CO -Trp-Cit- NH ; or 
 
 c) a tripeptide residue. 
 
 
     
 12. A compound according to  claim 1 , wherein
 a) a is 0 to 3; and/or 
 b) b is 0 to 12; and/or 
 c) d is 0 to 3. 
 
 
     
 13. A compound according to  claim 1 , wherein a is 0, c is 1 and d is 2, and b is from 0 to 8. 
 
     
 14. A compound according to  claim 1 , wherein the compound is of formula
 Id: 
 
 
 
 
 
   
   
 
 
 
 
     
 15. A conjugate of formula I:
   L-(D L ) p   (I)
 
 wherein L is a Ligand unit, D L  is a Drug Linker unit of formula I′: 
 
 
 
 
 
   
   
 
 
 wherein D, R 2 , R 6 , R 7 , R 9 , R 11b , Y, R″, Y′, D′, R 6′ , R 7′ , R 9′ , and R 12 , including the presence or absence of double bonds between C2 and C3 and C2′ and C3′ respectively, are as defined in  claim 1 ; 
 wherein p is an integer from 1 to 20; 
 R LL  is a linker for connection to a cell binding agent, which is: 
 
 
 
 
 
   
   
 
 
 where Q and X are as defined in  claim 1  and G LL  is selected from: 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 where Ar is phenylene. 
 
 
     
 16. A conjugate according to  claim 15 , wherein
 G LL  is selected from G LL1-1  and G LL1-2 . 
 
 
     
 17. A conjugate according to  claim 15 , wherein D L  is of formula (Id′): 
 
 
 
 
   
   
 
 
 
 
     
 18. A conjugate according to  claim 15 , wherein the Ligand Unit is an antibody or an active fragment thereof. 
 
     
 19. The conjugate according to  claim 18 , wherein the antibody or antibody fragment is an antibody or antibody fragment for a tumour-associated antigen, optionally wherein the antibody or antibody fragment is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(88):
 (1) BMPR1B; 
 (2) E16; 
 (3) STEAP1; 
 (4) 0772P; 
 (5) MPF; 
 (6) Napi3b; 
 (7) Sema 5b; 
 (8) PSCA hlg; 
 (9) ETBR; 
 (10) MSG783; 
 (11) STEAP2; 
 (12) TrpM4; 
 (13) CRIPTO; 
 (14) CD21; 
 (15) CD79b; 
 (16) FcRH2; 
 (17) HER2; 
 (18) NCA; 
 (19) MDP; 
 (20) IL20R-alpha; 
 (21) Brevican; 
 (22) EphB2R; 
 (23) ASLG659; 
 (24) PSCA; 
 (25) GEDA; 
 (26) BAFF-R; 
 (27) CD22; 
 (28) CD79a; 
 (29) CXCR5; 
 (30) HLA-DOB; 
 (31) P2X5; 
 (32) CD72; 
 (33) LY64; 
 (34) FcRH1; 
 (35) IRTA2; 
 (36) TENB2; 
 (37) PSMA—FOLH1; 
 (38) SST; 
 (38.1) SSTR2; 
 (38.2) SSTR5; 
 (38.3) SSTR1; 
 (38.4) SSTR3; 
 (38.5) SSTR4; 
 (39) ITGAV; 
 (40) ITGB6; 
 (41) CEACAM5; 
 (42) MET; 
 (43) MUC1; 
 (44) CA9; 
 (45) EGFRvIII; 
 (46) CD33; 
 (47) CD19; 
 (48) IL2RA; 
 (49) AXL; 
 (50) CD30—TNFRSF8; 
 (51) BCMA-TNFRSF17; 
 (52) CT Ags—CTA; 
 (53) CD174 (Lewis Y)—FUT3; 
 (54) CLEC14A; 
 (55) GRP78—HSPA5; 
 (56) CD70; 
 (57) Stem Cell specific antigens; 
 (58) ASG-5; 
 (59) ENPP3; 
 (60) PRR4; 
 (61) GCC-GUCY2C; 
 (62) Liv-1—SLC39A6; 
 (63) 5T4; 
 (64) CD56—NCMA1; 
 (65) CanAg; 
 (66) FOLR1; 
 (67) GPNMB; 
 (68) TIM-1—HAVCR1; 
 (69) RG-1/Prostate tumor target Mindin—Mindin/RG-1; 
 (70) B7-H4—VTCN1; 
 (71) PTK7; 
 (72) CD37; 
 (73) CD138—SDC1; 
 (74) CD74; 
 (75) Claudins—CLs; 
 (76) EGFR; 
 (77) Her3; 
 (78) RON—MST1R; 
 (79) EPHA2; 
 (80) CD20—MS4A1; 
 (81) Tenascin C—TNC; 
 (82) FAP; 
 (83) DKK-1; 
 (84) CD52; 
 (85) CS1—SLAMF7; 
 (86) Endoglin—ENG; 
 (87) Annexin Al—ANXA1; 
 (88) V-CAM (CD106)—VCAM1. 
 
 
     
 20. The conjugate of  claim 18  wherein the antibody or antibody fragment is a cysteine-engineered antibody. 
 
     
 21. The conjugate according to  claim 15  wherein p is an integer from 1 to 8. 
 
     
 22. A composition comprising a mixture of conjugates according to  claim 15 , wherein the average p in the mixture of conjugate compounds is about 1 to about 8. 
 
     
 23. A pharmaceutical composition comprising the conjugate of  claim 15  a pharmaceutically acceptable diluent, carrier or excipient. 
 
     
 24. A method of inhibiting growth of carcinoma cells which comprises contacting cancer cells with the pharmaceutical composition of  claim 23 , wherein the carcinoma cells are gastric carcinoma cells or breast carcinoma cells, and whereby growth of the cancer cells is inhibited. 
 
     
 25. The method of  claim 24 , wherein the carcinoma cells are in a human. 
 
     
 26. The method of  claim 24 , which further comprises contacting the carcinoma cells with a chemotherapeutic agent. 
 
   
 
 
 
 
 
 
 
 
